A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease : A Comprehensive Review from a Biological Perspective to Clinical Trial Results
Multiple myeloma (MM) is a genetically heterogeneous disease, in which the process of tumorigenesis begins and progresses through the appearance and accumulation of a tangle of genomic aberrations. Several are the mechanisms of DNA damage in MM, varying from single nucleotide substitutions to complex genomic events. The timing of appearance of aberrations is well studied due to the natural history of the disease, that usually progress from pre-malignant to malignant phase. Different kinds of aberrations carry different prognostic significance and have been associated with drug resistance in some studies. Certain genetic events are well known to be associated with prognosis and are incorporated in risk evaluation in MM at diagnosis in the revised International Scoring System (R-ISS). The significance of some other aberrations needs to be further explained. Since now, few phase 3 randomized trials included analysis on patient's outcomes according to genetic risk, and further studies are needed to obtain useful data to stratify the choice of initial and subsequent treatment in MM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Genes - 11(2020), 12 vom: 03. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sessa, Mariarosaria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| Anmerkungen: |
Date Completed 26.07.2021 Date Revised 04.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/genes11121453 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318529629 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318529629 | ||
| 003 | DE-627 | ||
| 005 | 20231226202309.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/genes11121453 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318529629 | ||
| 035 | |a (NLM)33287156 | ||
| 035 | |a (PII)E1453 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sessa, Mariarosaria |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease |b A Comprehensive Review from a Biological Perspective to Clinical Trial Results |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2021 | ||
| 500 | |a Date Revised 04.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Multiple myeloma (MM) is a genetically heterogeneous disease, in which the process of tumorigenesis begins and progresses through the appearance and accumulation of a tangle of genomic aberrations. Several are the mechanisms of DNA damage in MM, varying from single nucleotide substitutions to complex genomic events. The timing of appearance of aberrations is well studied due to the natural history of the disease, that usually progress from pre-malignant to malignant phase. Different kinds of aberrations carry different prognostic significance and have been associated with drug resistance in some studies. Certain genetic events are well known to be associated with prognosis and are incorporated in risk evaluation in MM at diagnosis in the revised International Scoring System (R-ISS). The significance of some other aberrations needs to be further explained. Since now, few phase 3 randomized trials included analysis on patient's outcomes according to genetic risk, and further studies are needed to obtain useful data to stratify the choice of initial and subsequent treatment in MM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Multiple Myeloma | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a genomic aberrations | |
| 700 | 1 | |a Cavazzini, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallari, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Rigolin, Gian Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Cuneo, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genes |d 2011 |g 11(2020), 12 vom: 03. Dez. |w (DE-627)NLM220446326 |x 2073-4425 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:12 |g day:03 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/genes11121453 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 12 |b 03 |c 12 | ||